4552 JCR Pharmaceuticals
- 636
- +11+1.76%
JCR Pharmaceuticals News
JCR Pharmaceuticals: Corporate Governance Report, July 12, 2024.
JCR Pharmaceuticals: JCR held an API factory tour for local residents.
JCR Pharmaceuticals: We held a factory tour for local residents.
JCR Pharmaceuticals: Announcements of individual stock: [Delayed] Notice of personnel and organizational changes.
JCR Pharmaceuticals: MEDIPAL and JCR have announced the completion of the clinical trial notification process for the phase I/II trial of JR-446 for mucopolysaccharidosis type IIIB in Japan.
JCR Pharmaceuticals: Acceptance of the investigational plan for Phase I/II trials of JR-446 for Mucopolysaccharidosis IIIB and completion of regulatory authority investigation regarding the clinical trial plan.
JCR Pharmaceuticals: Interim report
JCR Pharmaceuticals: Announcements of individual stocks regarding personnel changes and organizational restructuring.
JCR Pharmaceuticals: Matters related to the controlling shareholder (affiliated company).
JCR Pharmaceuticals: Regarding matters related to major shareholders (other affiliated companies).
JCR Pharmaceuticals: Correction: Consolidated financial statements (Japanese GAAP) for the fiscal year ending March 31, 2024 (fiscal year 2023)
JCR Pharmaceuticals: (Correction- Numerical Data Correction) Partial correction of the Financial results briefing[Japan Standard] (Consolidated) for the fiscal year ending March 2024.
JCR Pharmaceuticals: Confirmation letter
JCR Pharmaceuticals: Internal Control Report - 49th Term (2023/04/01 - 2024/03/31)
JCR Pharmaceuticals: Securities report - 49th period (April 1, 2023 - March 31, 2024)
JCR Pharmaceuticals: JCR Pharmaceuticals will regain full commodity rights for JR-141.
JCR Pharmaceuticals: Reacquisition of global sales rights for JR-141.
JCR Pharmaceuticals: Other electronic measures for providing materials for the 2024 regular shareholders' meeting.
JCR Pharmaceuticals: Other matters that will be subject to electronic provision measures at the 49th regular meeting of shareholders.
JCR Pharmaceuticals: Notice of the convocation of the 49th regular shareholder meeting.
Analysis
Price Target
No Data
